The main aim of this trial is to determine whether there are fewer cardiovascular events when patients with coronary artery disease take a low dose of colchicine of 0.5 mg daily on top of optimal standard treatment after treatment with PCI, compared with placebo in combination with optimal standard treatment. More specifically, we aim to investigate the benefits of a daily low dose of colchicine in patients with coronary artery disease after treatment with PCI, to confirm that a daily low dose of colchicine helps prevent additional incidents in coronary artery disease, and to identify a subgroup of patients with CAD who are at increased risk for cardiovascular events and could benefit most from colchicine.
Age ≥45 years.
Age ≥ year
Diabetes mellitus, on treatment or new diagnosis with HbA1c ≥6.5%
Current smoking
Women who are pregnant, breastfeeding, or of childbearing potential who are not using an effective method of contraception. Or women who intend to donate oocytes.
Men who plan to father children during the study period or who are unwilling to use effective forms of contraception. Or men who intend to donate sperm.
Any contraindication or known intolerance to colchicine.
Chronic use of -or need for- colchicine.
AZ Sint-Jan AV
Lead sponsor
University Hospital, Ghent
Collaborator
Belgium Health Care Knowledge Centre
Collaborator